Plantar Warts (Verruca Plantaris, Refractory)
Highly investigational use for refractory plantar warts (HPV-mediated) after cryotherapy and salicylic acid failure; very limited anecdotal evidence.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for plantar warts (verruca plantaris). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). Anecdotal only. Evidence-based first-line management of plantar warts is salicylic acid keratolytic therapy and cryotherapy (each with ~50-70% cure rates over 12-16 weeks). Refractory warts may respond to topical 5-fluorouracil, intralesional bleomycin, cantharidin, candida antigen injection, or laser ablation. Many plantar warts also resolve spontaneously over 12-24 months.
- Riesgos principales
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Spread of HPV to surrounding skin from disturbing the wart surface
- Painful prolonged bleeding from a thick keratinized plantar surface that does not seal easily
- Quién no debería considerar esto
- Patients with diabetes, peripheral arterial disease, or peripheral neuropathy (high foot-ulcer risk)
- Patients whose warts have not had a proper trial of salicylic acid, cryotherapy, or other standard therapy
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
- Qué preguntar a su clínico
- Have I tried salicylic acid for at least 12 weeks?
- Have I tried cryotherapy for 2-3 sessions?
- Have intralesional options like bleomycin or candida antigen been considered?
- What is the published cure rate for leeches versus a 70 percent cure rate for standard therapy?
- What is the bleeding-control plan on the bottom of the foot, where dressings shift with walking?
- How will viral spread to other foot skin be prevented?
- Cuándo buscar atención urgente
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Inability to bear weight on the foot due to pain or new wound
- Spreading streaks of redness up the foot or leg
Qué NO significa esto
- It does not mean leech therapy is FDA-cleared for plantar warts — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace standard therapy: salicylic acid, cryotherapy, and (for refractory cases) intralesional injections or laser.
- It does not eliminate the underlying HPV infection that caused the wart.
- It does not prevent recurrence at the same or new sites.
- It does not have controlled-trial evidence for this indication.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- dermatological
- ICD-10
- B07.0, B07.9
- Safety tier
- low
Evidence Summary
Plantar warts are HPV-mediated benign epithelial proliferations conventionally treated with topical salicylic acid (~60% efficacy) and cryotherapy (~50% efficacy), with second-line options including intralesional bleomycin or candida antigen, pulsed dye laser, or surgical paring with cantharidin. Direct evidence for leech therapy is limited to a single case report describing clearance of a longstanding giant plantar wart after medicinal leech application in an immunosuppressed patient; this is grade D anecdotal evidence, not a case series, and the mechanism is unclear (possible local immune stimulation). Most plantar warts resolve spontaneously over 1-2 years.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Singh K et al. (2020), n=12
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Mosaic warts covering >5 cm area (immune-targeted therapy preferred)
- Diabetic foot or peripheral neuropathy
- Immunocompromise predisposing to HPV proliferation
- Suspected verrucous carcinoma (biopsy required)
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.